Gamma Therapeutics is a biotech firm developing a novel class of biopharmaceutical and diagnostic test solutions for the cardiovascular disease industry based upon a clotting protein in blood (Gamma Prime Fibrinogen): a natural occurring protein in human blood. The protein is a carrier protein for factor XIII, a thrombin binding site, forms clots that are resistant to fibrinolysis, and is strongly and significantly associated with cardiovascular disease. Early tests performed at the Framingham Heart Study, the Stockholm Coronary Artery Risk Factor Study and othersâindicated that there is a correlation between high levels of Gamma Prime Fibrinogen and Total Fibrinogen and coronary heart disease. The Gamma Therapeutics product line includes its provisional-patented flagship product, GammaCoeur(tm), a cardiovascular disease risk diagnostic assay; GammaSeal(tm), a patent-pending, high strength post-surgical incision sealant, and; Gammarin(tm), a patented non-immunogenic blood anti-coagulant
